Clinical trials: TCM
Multiple Myeloma
An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells
The primary objective of this study is to evaluate tumor cell mobilization (TCM) with non-pegylated G-CSF alone compared with non-pegylated G-CSF plus plerixafor in patients with multiple myeloma (MM) who are potentially poor…
- Trial name
- NCT01753453
- Testing
- Plerixafor, Granulocyte-colony stimulating factor (G-CSF)
- Where
- 5 sites in Belgium, Estonia and 2 more
- Volunteers
- 23 people
- Sponsor
- Sanofi
Traumatic Brain Injury
NeuroAiD II™ (MLC901) in Mild Traumatic Brain Injury
A Randomized Double-blind, Placebo-controlled, Multi-center Trial to determine the efficacy of NeuroAiD II™ (MLC901) in improvement of cognitive functioning of adult patients with long-term cognitive impairment following mild…
- Trial name
- SAMURAI (NCT04861688)
- Testing
- Traditional Chinese Medicine (NeuroAiD II™ (MLC901)
- Where
- 4 sites in Russia
- Volunteers
- 182 people
- Sponsor
- Moleac Pte Ltd.
Colorectal Neoplasms, Diarrhea
Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer
The triple combination chemotherapy of irinotecan, 5-fluorouracil and leucovorin (CPT-11/5-FU/LV or Saltz regimen) is the treatment of choice for patients with advanced colorectal cancer.
- Trial name
- NCT00036517
- Testing
- PHY906
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- PhytoCeutica
Alopecia, Canities
6-Month Trial of Chinese Herbal Treatments for Hair Loss and Gray Hair
This will be a 6-month randomized, double-blind, placebo-controlled trial. A total of 152 participants with hair loss, including some with gray hair, will be enrolled and randomly assigned to four groups.
- Trial name
- NCT06998680
- Testing
- VitaGreen Capsule A+VitaGreen Tonic, VitaGreen Capsule B+VitaGreen Tonic
- Where
- China
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Vita Green Pharmaceutical (H.K.) Ltd.
Osteoarthritis, Knee
A Controlled Study of an Herbal Topical Patch in Treating Osteoarthritis (OA) of the Knee
An evaluation of the safety and efficacy of an herbal patch in treating osteoarthritis pain of the right or left knee.
- Trial name
- NCT01183624
- Testing
- Herbal Patch
- Where
- 12 sites in China
- Volunteers
- 626 people
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Idiopathic Infertility, Infertility Unexplained
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility
The goal of this clinical trial is to determine whether telomere profiling and other biological aging hallmarks can help identify underlying mechanisms of persistent infertility in women with post-treatment unexplained…
- Conditions
- Idiopathic Infertility, Infertility Unexplained, Infertility (IVF Patients), Infertility Assisted Reproductive Technology
- Trial name
- TECMI (NCT07404969)
- Testing
- 1. Aging Hallmarks Biomarker Profiling (Telomere-Based), 2. Integrative Botanical and Nutraceutical Intervention, 3. Natural Conception or Assisted Reproductive Technologies
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- BEYOND GENOMiX SA, AG, Ltd
Hepatocellular Carcinoma, Liver Cancer
Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma
Capecitabine is a chemotherapeutic that has been approved for use in breast and colorectal cancers. The advantages of capecitabine are that (1) it is an oral drug; and (2) it is less toxic than many other chemotherapeutics.
- Trial name
- NCT00076609
- Testing
- PHY906, capecitabine
- Where
- 5 sites in United States, Taiwan
- Volunteers
- 31 people
- Sponsor
- PhytoCeutica
Colorectal Adenoma, High Risk
Shenbai Granules for Preventing Malignant Transformation of High-risk Colorectal Adenomas
This multicenter, randomized, double-blind, placebo-controlled trial will enroll 450 patients with completely resected high-risk colorectal adenoma (HR-CRA), randomly assigned (1:1) to 6 months of Shenbai Granules (SBG) or…
- Conditions
- Colorectal Adenoma, High Risk, TCM
- Trial name
- NCT07129499
- Testing
- Shenbai Granules
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
Stroke, Cerebral Infarction
Study of NeuroAid In Enhancing Recovery After Stroke
TIERS is a phase II to generate detailed preliminary data on the efficacy of NeuroAid in post-stroke recovery, and to assess the utility of the rehabilitation outcome measure instruments used.
- Trial name
- TIERS (NCT00721825)
- Testing
- Neuroaid
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Moleac Pte Ltd.
Rectal Cancer, Lung Cancer
A Phase I Clinical Trial of Bevacizumab Injection
Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor (bevacizumab) is Avastin produced by Zhengda Tianqing Pharmaceutical Group Co., Ltd Biological similar drugs.
- Conditions
- Rectal Cancer, Lung Cancer, Ovarian Cancer, Cervical Cancer
- Trial name
- NCT05476341
- Testing
- Bevacizumab injection, Bevacizumab injection（Avastin）
- Where
- China
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Tourette Syndrome
Evaluate the Efficacy, Safety and Tolerability of TSUPPORT for Adults With Tourette Syndrome
A 28-week single-arm trial to evaluate the efficacy, safety and tolerability of TSupport (a Traditional Chinese Medicine) for adults with Tourette Syndrome.
- Trial name
- NCT05183594
- Testing
- TSupport (a Traditional Chinese Medicine)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Tasly Pharmaceuticals, Inc.
Colorectal Adenoma, TCM
Shenbai Granules for Preventing Recurrence of Low-Risk Colorectal Adenomas
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shenbai Granules for Preventing Recurrence of Low-Risk Colorectal Adenomas（LRCRA）.
- Conditions
- Colorectal Adenoma, TCM, Low Risk
- Trial name
- NCT07123116
- Testing
- Shenbai Granules
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
Colon Cancer
Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer
This study is designed as a multi-center, randomized, double-blind, placebo-controlled trial. Subjects in the intervention group will be treated with XLJDOD compound granule.
- Trial name
- NCT05709249
- Testing
- XLJDOD compound granule
- Where
- China
- Volunteers
- 730 people
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
Stable Angina Pectoris
Efficacy and Safety Study of Total Flavonoids of Propolis Dropping Pill to Treat Angina Pectoris
The purpose of this study is to confirm the efficacy and safety of total flavonoids of propolis dropping pill to treat angina pectoris, evaluated by total exercise time of treadmill exercise test.
- Trial name
- NCT01453582
- Testing
- Total Flavonoids of Propolis dropping pill
- Where
- 13 sites in China
- Volunteers
- 478 people
- Sponsor
- Shanghai Greenvalley Pharmaceutical Co., Ltd.
Memory Impairment, Dementia, Vascular
CognivAiD Real-World Evidence Clinical Registry (CONNECT Registry)
This is an observational, prospective cohort of patients who were prescribed or have taken CognivAiD as prescribed by the attending physician. The safety and efficacy of CognivAiD have been established in clinical studies.
- Trial name
- CONNECT (NCT06228638)
- Testing
- CognivAID (Sailuotong)
- Where
- Singapore
- Volunteers
- 100 people
- Sponsor
- Moleac Pte Ltd.
Protective Qi Insufficiency (a Condition Term From TCM)
A Follow-up Trial of Proglucamune® in the Treatment of Protective Qi Deficiency, a TCM Condition
This is a follow-up Phase II study of a previously complete pilot trial (Protocol ID: 201875) with the same goal: evaluating the activity of Proglucamune on Protective Qi (PQi) Insufficiency.
- Trial name
- NCT03782974
- Testing
- beta glucan
- Where
- Canada
- Volunteers
- 207 people
- Sponsor
- USANA Health Sciences
COVID-19
TCM Differentiation and Treatment Protocol of COVID-19
Evaluation of the efficacy and safety of TCM differential treatment of COVID-19 in Jiangsu Province based on the historical prospective multicenter cohort study.
- Trial name
- TDATPOC (NCT04306497)
- Testing
- TCM prescriptions
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
Allergy to Fish, Allergy to Shrimp
Pilot Study on Traditional Chinese Medicine and Food Allergy
Recently, there has been an increasing interest in using traditional Chinese medicine for food allergy. The Harvard group has successfully demonstrated the Food Allergy Herbal Formula - FAHF2 completely blocked peanut-induced…
- Conditions
- Allergy to Fish, Allergy to Shrimp, Allergy to Crab
- Trial name
- TCMFA (NCT02490813)
- Testing
- Treatment - Chinese Herbal Formula - X
- Where
- Hong Kong
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Hong Kong Sanatorium & Hospital
Cholangiocarcinoma
Clinical Trial of Autologous Tcm Immunotherapy in ICC
The prime purpose of this trial is to evaluate the Progression Free survival and two-year survival of combining autologous Tcm cellular immunotherapy and traditional therapy in intrahepatic cholangiocarcinoma (ICC) patients after…
- Trial name
- NCT03820310
- Testing
- autologous Tcm cellular immunotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Newish Technology (Beijing) Co., Ltd.
Hand, Foot, and Mouth Disease
Effectiveness and Safety of Chinese Medicine to Treat Hand, Foot, and Mouth Disease
The study is aimed to evaluate the effectiveness and safety of Xiyanping injection,a traditional Chinese medicine (TCM), in the treatment of severe type of hand, foot, and mouth disease (HFMD).
- Trial name
- NCT01554930
- Testing
- Western therapy (mannitol, methylprednisolone, immunoglobulin, febrifuge), Xiyanping injection plus western therapy
- Where
- 3 sites in China
- Volunteers
- 230 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.